0000000000275708

AUTHOR

Christina Krienke

showing 2 related works from this author

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis.

2019

Precision therapy for immune tolerance Autoimmune diseases, such as multiple sclerosis (MS), result from a breach of immunological self-tolerance and tissue damage by autoreactive T lymphocytes. Current treatments can cause systemic immune suppression and side effects such as increased risk of infections. Krienke et al. designed a messenger RNA vaccine strategy that lacks adjuvant activity and delivers MS autoantigens into lymphoid dendritic cells. This approach expands a distinct type of antigen-specific effector regulatory T cell that suppresses autoreactivity against targeted autoantigens and promotes bystander suppression of autoreactive T cells against other myelin-specific autoantigen…

Encephalomyelitis Autoimmune ExperimentalMultiple SclerosisRegulatory T cellEncephalomyelitisAntigen presentationAntigen-Presenting CellsAutoantigensT-Lymphocytes RegulatoryMiceImmune systemAntigenmedicineAnimalsRNA MessengerAntigen-presenting cellImmunosuppression TherapyInflammationVaccines SyntheticMultidisciplinarybusiness.industryEffectorExperimental autoimmune encephalomyelitisBystander Effectmedicine.diseaseMice Inbred C57BLmedicine.anatomical_structureImmunologybusinessPseudouridineScience (New York, N.Y.)
researchProduct

CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

2015

The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research...

0301 basic medicineOncologymedicine.medical_specialtyCombination therapymedicine.medical_treatmentImmunologyMeeting Reportcombination therapyCell therapy03 medical and health sciencesCancer immunotherapyInternal medicinemedicineImmunology and Allergytumor microenvironmentPersonalized therapytumor vaccinationPharmacologypersonalized therapyTumor microenvironmentcancer immunotherapybusiness.industryCIMTcellular therapy030104 developmental biologyImmunologybusinessHuman Vaccines & Immunotherapeutics
researchProduct